Use case
Unverified: the hadrian.co pages in evidence describe rebuilding American manufacturing output, unrelated to security engineers running penetration tests; it cannot be confirmed who handles what material in what situation to complete what task.
Unverified: no public material states whether security teams currently substitute with manual penetration testing, vulnerability scanners or anything else.
Unverified: the evidence contains no pain statement about penetration-test scheduling, coverage or vulnerability validation, only manufacturing-output narratives and unrelated encyclopedia/AI-assistant pages.
xOcto's call
Useful problem, weak urgency
Trend: offensive security testing is moving from scheduled manual engagements toward continuous automation, bought by enterprise security teams that already hold compliance and security budgets. Entry: start from recurring penetration-testing compliance needs in regulated sectors (finance, healthcare, critical infrastructure) and charge per test cycle or per covered asset rather than per seat; pricing is not disclosed in public materials and this is an inference.
Reason to use it
Why users would choose it
Unverified: the evidence cannot explain what concrete action reduces which step's burden, nor which users would choose it in what situation; funding news is attention evidence only and cannot explain usage motivation.
Where the easy answer breaks down
The tension worth following
An English validation note will follow from the public evidence.
If this is your job
Clue only. Unverified: the evidence cannot explain what concrete action reduces which step's burden, nor which users would choose it in what situation; funding news is attention evidence only and cannot explain usage motivation.
Entry and what to borrow
Trend: offensive security testing is moving from scheduled manual engagements toward continuous automation, bought by enterprise security teams that already hold compliance and security budgets. Entry: start from recurring penetration-testing compliance needs in regulated sectors (finance, healthcare, critical infrastructure) and charge per test cycle or per covered asset rather than per seat; pricing is not disclosed in public materials and this is an inference.